TTRX · Turn Therapeutics Inc.
$7.70
-0.08 (-1.03%)
At close · Jul 28
Going-concern doubt
— flagged May 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our capital resources may not be sufficient to fund operations through at least the next 12 months from the date that these unaudited condensed consolidated financial statements as of March 31, 2026 are issued based on our expected cash needs, which raises substantial doubt about our ability to continue as a going concern.”View the 10-Q filed May 11, 2026
Market Cap
$229.37M
Shares
29.79M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.70
Open$7.81
Day$7.65–8.18
52W$2.57–26.50
Avg vol 30d102K
Short int58K · 0.2% float · 1.0d
Short vol71%
DataOct 2025–Jul 2026
Filing10-Q · May 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+65%
above
Price vs 50-day avg
+13%
above
RSI (14)
46
neutral
MACD trend
Negative
52-week position
21%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+11%
trailing
6-month return
+84%
trailing
YTD return
+95%
this year
Relative strength
+77%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $5 — 50d above 200d
Institutional flow
Accumulating
7 of 20 funds reported for Jun 30 · net +319.3K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.19% of float · ▲ +49.9% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
20 holders — 13F breadth
Squeeze score
45
elevated · 0–100
Fundamentals
EPS growth
−71%
Y/Y
Balance sheet
$4.0M
net cash
Quant / Vol
risk profile
Volatility
114%
annualized · 1-yr
Max drawdown
−71%
past year
ATR
11.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+65%
Bullish
Price vs 50-day avg
+13%
Bullish
RSI (14)
46
Neutral
MACD trend
Negative
Bearish
52-week position
21%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $7 › 200d $5 — 50d above 200d
Institutional flow
Accumulating
7 of 20 funds reported for Jun 30 · net +319.3K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.19% of float · ▲ +49.9% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
20 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $3
Now $8 · 21%
52-wk high $27
vs 200-day avg +65%
vs 50-day avg +13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TTRX
this stock
Turn Therapeutics Inc.
|
$229.37M | +95.4% | — | — | 0.2% |
|
ONC
BeOne Medicines Ltd.
|
$477.60B | +7.3% | +22179.2% | 971.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TTRX | -23.4% | +11.1% | +84.2% | +5.5% | +95.4% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -22.4% | +11.1% | +76.8% | +6.3% | +86.8% |